Table 2.

Serious adverse events and cases in which primaquine was stopped

Arm	Gender	Syndrome	Relation to study drug	Hb d0	Hb d1	Hb d2	Hb d7	G6PD genotype*	Action
Serious adverse events
CQ	F	Vomiting	Unlikely	9.3	9.2	–	–	WT	Hospitalized d1
CQ+PQ	F	Jaundice	Possible	13	13	11	–	WT	Hospitalized d2
CQ+PQ	M	Dyspnoea	Possible	14.2	–	13.5	13.2	–	Hospitalized d7
CQ+PQ	M	Jaundice, dark oliguria	Possible	9.8	–	9.2	8.5	–	Hospitalized d2
CQ+PQ	F	Anemia, tachycardia	Possible	10.4	–	10.5	9.8	WT	Hospitalized d7
CQ+PQ	F	Hypotension, dark urine, jaundice	Possible	13.0	12.0	12.0	12.0	WT	Hospitalized d7
CQ+PQ	F	Vomiting, food poisoning	Unlikely	10.2	–	–	–	WT	Hospitalized d1
Other cases where PQ was stopped or jaundice described
CQ	F	Jaundice, dizziness	Possible	9.0	8.6	8.5	8.6	WT	No action taken
CQ+PQ	M	Face swelling, dyspnea, dark urine	Possible	13.2	13.2	12.5	13.4	WT	PQ stopped d1
CQ+PQ	M	Dark urine	Possible	14.5	–	–	12.8	–	PQ stopped d7
CQ+PQ	M	Jaundice, dark urine	Possible	9.2	–	9.4	10.0	WT	PQ stopped d2
CQ+PQ	M	Jaundice, dark urine, dyspnoea	Possible	10.4	–	9.8	10.2	–	PQ stopped d2
CQ+PQ	F	Jaundice, dark oliguria, dyspnoea	Possible	9.3	–	9.0	8.8	WT	PQ stopped d7
CQ+PQ	M	Jaundice, dark urine, dyspnoea	Possible	8.8	–	8.7	7.5	WT	PQ stopped d7

CQ = chloroquine; PQ = primaquine.

^*G6PD genotype (hemizygous or homozygous) at the Mediterranean locus (563C>T mutation).